Symphony Capital, an American private-equity firm with $315m allocated to drug-development financing, has done some two dozen unorthodox deals in which it pours money into new joint ventures in return for control of a firm\'s intellectual-property rights.
Symphony Capital, an American private-equity firm with $315m allocated to drug-development financing, has done some two dozen unorthodox deals in which it pours money into new joint ventures in return for control of a firm\'s intellectual-property rights.
美国私人股本公司交响资金划出3.15亿美元用于药品开发融资，在二十几庄不符合惯例的交易中，它向新成立的合资公司大笔注入资金，以换得对其知识产权的控制。